Presentations–Targeting New Molecular Drivers in NSCLC - priME Oncology
prIME Downloadable Slides
prIME Downloadable Slides

Presentations–Targeting New Molecular Drivers in NSCLC

Emerging Data Under the Magnifying Glass

Not a member of My prIME? Join now for instant access.

These downloadable slides focus on emerging targeted therapy options for new actionable molecular drivers in non-small cell cancer (NSCLC). Topics addressed include advances in molecular testing, such as next-generation sequencing and liquid biopsy; new data on emerging agents; and how these new data should be applied in clinical practice.

Downloadable Slides

Downloadable Slides

Release Date

Release Date

Nov 9, 2018

Expiration Date

Nov 9, 2019

Featured Expert

  • Ming Sound Tsao, MD, FRCPC, Princess Margaret Cancer Center, Toronto, Ontario, Canada

Featured Topic

Why, when, and how to incorporate broad molecular profiling into routine management of lung cancer

Featured Expert

  • Terufumi Kato, MD, Kanagawa Cancer Center, Yokohama, Japan

Featured Topic

Targeting c-MET in advanced NSCLC

Featured Expert

  • Tony Mok, MD, FRCP, The Chinese University of Hong Kong, Hong Kong, China

Featured Topic

Targeting HER2, RET, and NTRK

Featured Expert

  • James C-H Yang, MD, PhD, National Taiwan University Hospital, National Taiwan University Cancer Center, Taipei, Taiwan

Featured Topic

Targeting acquired resistance to EGFR kinase inhibitors: Beyond T790M mutation

Featured Expert

  • Tony Mok, MD, FRCP, The Chinese University of Hong Kong, Hong Kong, China

Featured Topic

prIME Points

This educational activity is intended for medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, pathologists, oncology fellows, and other healthcare professionals involved in the management of patients with lung cancer in Asia.

After successful completion of this educational activity, participants should be able to:

  • Assess and apply molecular testing methods in advanced NSCLC, including next-generation sequencing (NGS) and use of liquid biopsy
  • Evaluate the role of potential new actionable oncogene drivers such as MET amplification and exon 14–skipping mutations
  • Analyze efficacy and safety data of emerging agents in patients harboring rare driver mutations
  • Explain mechanisms of acquired resistance to EGFR TKIs and strategies for overcoming resistance

This educational activity is supported by a grant from Merck KGaA, Darmstadt, Germany.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of IME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality IME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Kato has disclosed employment by his spouse at Eli Lilly. He has also disclosed honoraria for promotional speaker’s bureaus from AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai, Eli Lilly, MSD, Novartis, Ono, Pfizer, Quintiles, F. Hoffmann-La Roche Ltd, and Taiho. He has also disclosed independent contracting for AbbVie, Astellas, AstraZeneca, Bristol-Myers Squibb, Chugai, Eli Lilly, Kirin-Kyowa, Merck Serono, MSD, Ono, Pfizer, Quintiles, and Parexel. He has disclosed membership on advisory committees or review panels for AstraZeneca, Boehringer Ingelheim, Chugai, Eli Lilly, MSD, and Ono. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Mok has disclosed board membership with ASCO, Asian Thoracic Oncology Research Group (ATORG), Chinese Lung Cancer Research Foundation Ltd., Chinese Society of Clinical Oncology (CSCO), Hong Kong Cancer Therapy Society (HKCTS), Hutchison Chi-Med, IASLC, and St. Stephen’s College & Prep. School Hong Kong. He has also disclosed consulting fees for advisory boards and public lectures from AstraZeneca; ACEA Biosciences, Inc; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eli Lilly; Fishawack Facilitate Ltd; Hengrui Therapeutics Inc.; Hutchison Chi-Med; Ignyta, Inc.; Janssen; Merck Serono, MSD; Novartis; OncoGenex Pharmaceuticals, Inc.; OrigiMed; Pfizer; Roche/Genentech; Sanofi-Aventis R&D; SFJ Pharmaceutical; Takeda Oncology; Vertex Pharmaceuticals; and Yuhan Corporation. He has disclosed independent contracting for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb; Clovis Oncology, MSD, Novartis, Pfizer, Roche, SFJ Pharmaceuticals, and Xcovery. He has disclosed ownership interest in Hutchison Chi-Med and Sanomics Ltd. He has disclosed speaking and teaching at public lectures or conference symposia for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, MSD, Novartis, Pfizer, Roche/Genentech, Taiho, and Takeda Oncology. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Tsao has disclosed consulting fees from AbbVie, AstraZeneca, Bristol-Myers Squibb, Celgene, Merck, and Pfizer. He has also disclosed independent contracting for AstraZeneca. He has disclosed speaking and teaching for Merck. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Yang has disclosed that he has received honoraria for lectures or participated in compensated advisory boards for Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Daiichi Sankyo, Eli Lilly, Hansoh Pharmaceutical, Merck Serono, Merrimack, MSD, Novartis, Ono Pharmaceutical, Pfizer, Roche/Genentech/Chugai, Takeda, and Yuhan Pharmaceuticals. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Bojana Pajk, MD, MSc (medical director content reviewer/planner) – no relevant financial relationships
  • Amy Furedy, RN, OCN (scientific content reviewer/planner) – no relevant financial relationships
  • Heather Tomlinson, ELS (editorial content reviewer) – no relevant financial relationships

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.